Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer-Reference-Cited by-同舟云学术

Current Status of Prostate-Specific Membrane Antigen Targeting in Nuclear Medicine: Clinical Translation of Chelator Containing Prostate-Specific Membrane Antigen Ligands Into Diagnostics and Therapy for Prostate Cancer

Published:2016-09 Issue:5 Volume:46 Page:405-418
ISSN:0001-2998
Container-title:Seminars in Nuclear Medicine
language:en
Short-container-title:Seminars in Nuclear Medicine

Author:

Kratochwil Clemens,Afshar-Oromieh Ali,Kopka Klaus,Haberkorn Uwe,Giesel Frederik L.

Publisher

Elsevier BV

Subject

Radiology, Nuclear Medicine and imaging

Reference107 articles.

1. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations);Howlader,2012

2. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries in 2012;Ferlay;Eur J Cancer,2013

3. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010;Lozano;Lancet,2012

4. Multiparametric prostate magnetic resonance imaging in the evaluation of prostate cancer;Turkbey;CA Cancer J Clin,2015

5. PET/CT imaging and radioimmunotherapy of prostate cancer;Bouchelouche;Semin Nucl Med,2011

Cited by 67 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Tumor targeted alpha particle therapy with an actinium-225 labelled antibody for carbonic anhydrase IX;Chemical Science;2024

2. Evaluation and management of dry mouth and its complications in rheumatology practice;Expert Review of Clinical Immunology;2023-11-02

3. Theranostic Nuclear Medicine with Gallium-68, Lutetium-177, Copper-64/67, Actinium-225, and Lead-212/203 Radionuclides;Chemical Reviews;2023-10-05

4. Multicentric 68Ga-PSMA PET radiomics for treatment response assessment of 177Lu-PSMA-617 radioligand therapy in patients with metastatic castration-resistant prostate cancer;Frontiers in Nuclear Medicine;2023-09-14

5. Preclinical Development in Radiopharmaceutical Therapy for Prostate Cancer;Seminars in Nuclear Medicine;2023-09